Scientific research into the gut microbiome has uncovered promising potential in Bacteroides species, with innovative applications spanning metabolic disorders, inflammatory conditions, and neurological health. Creative Biolabs has responded to this emerging field by developing a sophisticated platform dedicated to exploring and leveraging these complex bacterial strains.
The company has established an advanced workflow for isolating and identifying Bacteroides strains using cutting-edge techniques including anaerobic cultivation, 16S rRNA sequencing, whole-genome sequencing, and mass spectrometry. This comprehensive approach allows researchers to selectively enrich target strains from diverse sample sources.
Researchers at Creative Biolabs can access multi-dimensional assessment services that evaluate critical functional characteristics of Bacteroides strains. These evaluations include analyzing short-chain fatty acid production, polysaccharide degradation activity, intestinal cell adhesion, pathogen exclusion capabilities, and immune modulation potential.
Biosafety remains a critical consideration in the research process. The platform incorporates extensive safety screening, including whole-genome analysis to identify potential virulence factors and resistance genes. Additional comprehensive safety checks examine hemolytic activity, toxin production, metabolic byproduct toxicity, and cytotoxicity.
The upgraded platform has already integrated several key Bacteroides species, including B. fragilis, B. ovatus, and B. thetaiotaomicron. Some strains have completed preliminary functional validation and are available as high-activity reference strains for collaborative research.
By providing laboratory-scale production services, the company supports researchers in anaerobic fermentation process optimization, biomass harvesting, lyophilization, and quality control. These capabilities enable further functional validation, mechanism research, and early-stage formulation development in the rapidly evolving field of microbiome therapeutics.
